ABVC BioPharma, Inc.
ABVC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.01 | -0.61 | -3.31 |
| FCF Yield | -26.27% | -83.67% | -37.99% | -8.97% |
| EV / EBITDA | -2.12 | -1.12 | -1.44 | -7.51 |
| Quality | ||||
| ROIC | -116.69% | -167.34% | -188.61% | -95.79% |
| Gross Margin | 99.85% | -98.15% | 70.47% | 98.57% |
| Cash Conversion Ratio | 0.34 | 0.54 | 0.45 | 0.63 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.30% | -24.61% | 26.15% | -20.26% |
| Free Cash Flow Growth | 57.01% | 44.03% | 1.28% | -66.86% |
| Safety | ||||
| Net Debt / EBITDA | -0.54 | -0.32 | -0.13 | 0.23 |
| Interest Coverage | -5.70 | -5.15 | -51.42 | -51.52 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.20 |
| Cash Conversion Cycle | 827.32 | 1,818.81 | 515.44 | 2,301.22 |